Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
University of Dundee to establish potential of investigational compound to improve outcomes in COVID-19 progression in trial of 300 patients
Research title
A randomised, double-blind, placebo-controlled trial of SFX-01 or placebo on a backbone of best standard care, to improve outcomes in COVID-19 progression
Summary
University of Dundee and Evgen Pharma PLC, with funding from LifeArc, are set to commence clinical trial testing of an investigational medicinal product in 300 hospitalised COVID-19 patients. Researchers have identified that one of Evgen’s existing products, SFX-01, could reduce the impact of COVID-19 disease by preventing Acute Respiratory Distress Syndrome (ARDS), a common and often deadly symptom of severe cases of COVID-19.
Research organisations
University of Dundee
Evgen Pharma PLC
Researchers
Principal Investigator:
Professor James Chalmers, University of Dundee
Co-investigators:
Albena Dinkova-Kostova, University of DundeePotential of repurposed therapeutic for COVID-19 pandemic
A major challenge in the treatment of COVID-19 is the development of slowly worsening lung damage, known as Acute Respiratory Distress Syndrome (ARDS). This requires intensive care treatment with ventilation until the inflammation is resolved and the lungs can heal.
Nrf2 is a transcription factor (a naturally-occurring protein) which forms part of the body’s defences against inflammatory and oxidative stress, such as the inflammation that occurs during a severe viral infection. It is hypothesised that increasing the levels of active Nrf2 in patients with COVID-19 could improve recovery and prevent the need for ventilation.
SFX-01, a stable form of the natural compound sulforaphane, is an orally administered investigational medicinal product that activates Nrf2 and has been tested in over 130 patients to date in clinical trials (in healthy volunteers and patients suffering from breast cancer or a rare type of brain haemorrhage).
Researchers secured funding from LifeArc to conduct an investigator led, prospective, randomised, double-blind placebo-controlled trial, conducted in the UK, of patients hospitalised with COVID-19.
Investigating a sample size of 300 subjects, the study will compare outcomes for 300mg SFX-01 taken orally, once daily, plus best standard of care (BSC) versus placebo taken orally, once daily plus BSC. The primary outcome of the trial is the clinical status of patients on day 15 based on a seven point scale, recommended by the World Health Organisation as the optimal clinical trial endpoint for COVID-19 studies.
The trial will be conducted in up to six sites across Scotland and the north of England with first patient visit anticipated to happen in July.
Prof Albena Dinkova-Kostova project research website also updated;
Status Active
Effective start/end date
1/05/20 ? 30/04/21
https://discovery.dundee.ac.uk/en/projects/a-randomized-controlled-trial-of-sfx-01-to-improve-clinical-outco
UP and running since 1/5/20.....!!!??? Gla :')
https://discovery.dundee.ac.uk/en/persons/james-chalmers/projects/?status=RUNNING
With EVG don't assume anything ....
Wait for the RNS stating that they have started :-)
Btw I'm assuming the trial now being 'active' means the actual trial is now starting i.e. the patient recruitment that started in July has reached its target.
COVID-19 trial finally up and running
https://discovery.dundee.ac.uk/en/projects/a-randomized-controlled-trial-of-sfx-01-to-improve-clinical-outco